A new study has shown that blood tests can estimate a woman’s risk of cardiovascular disease over the next three decades. Which Allows for a 30-year evaluation of women’s heart disease risks.
The study in London showed for the first time that simple blood tests can estimate a woman’s risk of cardiovascular disease over the next three decades.
This information is essential for patients and manufacturers of cholesterol-lowering drugs, anti-inflammatory drugs, and lipoprotein(a)- lowering drugs, as the implications for therapy are broad.
The 27939 participants in the Women’s Health Initiative study had blood tests between 1992 and 1995 for low-density lipoprotein cholesterol (LDL-C). High-sensitivity C-reactive protein (hsCRP), and lipoprotein(a), a genetically determined type of fat.
Risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of each marker.
70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a). The three biomarkers are independent of each other and tell us about different biological issues each woman faces.
The therapies we might use in response to an elevation in each biomarker are markedly different. Pysicians can now specifically target the individual’s biological problem.
While drugs that lower LDL-C and hsCRP are widely available, companies like Novartis, Amgen, Eli Lilly, and Silence Therapeutics. As they will be still developing drugs that reduce lipoprotein (a) levels. Sometimes, lifestyle changes such as exercising and quitting smoking can be helpful.
Click to read more about Health
